Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

 

Director Nominees

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

WITHHELD

FOR

WITHHELD

Daniel N. Chicoine

6,490,732

109,026

98.3%

1.7%

Anthony E. Dobranowski

6,508,888

90,870

98.6%

1.4%

John C. London

6,533,190

66,568

99.0%

1.0%

Deborah Shannon-Trudeau

6,541,297

58,461

99.1%

0.9%

Serge Verreault

6,590,211

9,547

99.9%

0.1%

Reappointment of External Auditors

 

Outcome

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

WITHHELD

FOR

WITHHELD

Ernst & Young LLP reappointed

7,212,551

148,556

98.0%

2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

 

Outcome

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

AGAINST

FOR

AGAINST

Share Incentive Plan approved

6,526,477

73,281

98.9%

1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606355142/en/

Linda Kisa, CPA, CA Vice-President, Reporting and Corporate Affairs Email: [e-mail]